drugset / Trial / NCT01782495

A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients

NCT01782495

Phase 2 Completed 129 enrolled AbbVie
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of ABT-450/r/ABT-267 with or without ABT-333 and with or without ribavirin (RBV) in adult liver or renal transplant recipients with hepatitis C virus (HCV) genotype 1 or 4 (GT1 or GT4) infection.

Timeline

Start
2013-02-25
Primary completion
2016-11-02
Completion
2017-07-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Ribavirin Small molecule 1000 mg
Subject Ribavirin Small molecule 1200 mg
Subject Ritonavir Other / unclassified 100 mg
Subject dasabuvir Small molecule 250 mg
Subject ombitasvir Small molecule 25 mg
Subject paritaprevir Small molecule 150 mg